Medshine Discovery Inc. has presented new pyrimidine derivatives acting as leucine-rich repeat serine/threonine-protein kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of neurodegeneration.

Jacobio Pharmaceuticals Co. Ltd. has identified new stimulator of interferon genes protein (STING; TMEM173) agonists reported to be useful for the treatment of cancer.

The Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO) has presented new imidazo[1,2-b]pyridazine-based tricyclic compounds acting as serine/threonine-protein kinase haspin (GSG2) inhibitors and reported to be useful for the treatment of cancer.

Chiesi Farmaceutici SpA has described new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).

Vicore Pharma AB has divulged new angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of rheumatoid arthritis, diabetic nephropathy, pulmonary arterial hypertension, myocardial infarction, pneumonia viral, sarcoidosis, idiopathic pulmonary fibrosis and systemic scleroderma (systemic sclerosis), among other disorders.

Zymeworks Inc. has described new antibody-drug conjugates (ADCs) consisting of a cysteine engineered full-length antibody (IgG type) targeting hepatocyte growth factor receptor (HGFR; MET) or folate receptor α (FOLR1; FR- α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Suzhou Zelgen Biosciences Co. Ltd. has identified new compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Keythera (Suzhou) Pharmaceuticals Co. Ltd. has divulged new tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of alopecia areata, rheumatoid arthritis, lupus erythematosus, inflammation, allergy, cancer, metabolic diseases and transplant rejection, among other disorders.

Medshine Discovery Inc. has disclosed new benzylaminoquinazoline derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.

Impact Therapeutics Inc. has described five-membered heteroaryl-pyrimidine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.